Functional sites for anesthetics in GABAA receptors. by Maldifassi, Maria Constanza & Sigel, Erwin
Oncotarget10779www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/                 Oncotarget, 2017, Vol. 8, (No. 7), pp: 10779-10780
Functional sites for anesthetics in GABAA receptors
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A key target for the intravenous anesthetics propofol 
and etomidate is the γ-aminobutyric acid type A (GABAA) 
receptor [1]. GABAA receptors are the most important 
inhibitory neurotransmitter receptors in the central 
nervous system. They are composed of five subunits 
that surround a central Cl- selective ion channel. Each 
subunit has an extracellular domain, four trans-membrane 
domains, and a variable-size intracellular loop. The major 
receptor isoform is composed of α1, β2, and γ2 subunits, 
arranged counter clockwise γ2β2α1β2α1 as seen from the 
cell exterior [for review see 2 and references therein]. In 
α1β2γ2 GABAA receptors there are five subunit interfaces: 
two β+/α- interfaces, and one of each α+/β-
, 
α+/γ-, and 
γ+/β-; where the sidedness of the subunits is designated 
+ and -. Figure 1 shows a schematic representation of a 
cross section of the receptor near the extracellular surface 
of the membrane. Two GABA binding sites are located at 
the β+/α- extracellular subunit interfaces. 
Earlier efforts to identify binding sites for 
intravenous anesthetics on GABAA receptors used 
mutational analysis, sometimes combined with cysteine 
modification, or photoaffinity labeling [for review see 
3 and references therein]. Photoaffinity labeling using 
photo-reactive analogs of anesthetics is a powerful 
method to identify amino acid residues located in or close 
to the binding pocket of the anesthetic by an irreversible 
covalent reaction. All residues identified with this method 
were located at subunit interfaces in the trans-membrane 
domain. Although this method has the advantage that it is 
able to point out single amino acid residues involved in 
binding, it largely ignores their functional relevance. 
Until now mutational approaches have concentrated 
on a limited number of subunit interfaces, without 
resolving them. One of the residues identified here was 
β2N265. We used mutation of this and homologous 
residues in other subunits as reporter mutations to 
investigate the functional importance of all subunit 
interfaces for potentiation by the anesthetics etomidate and 
propofol [4]. The mutations were N265I, in the β2 subunit 
and S269I and S280I in the α1 and γ2 subunits. Receptors 
were expressed in Xenopus oocytes, and characterized 
using two electrode voltage-clamp electrophysiology. 
In the triply mutated receptor, which combines 
mutations at all interfaces, potentiation by both anesthetics 
was eliminated [4]. In receptors carrying the reporter 
mutation in the α+/β- or α+/γ- interfaces, i.e. α1S269Iβ2γ2 
receptors, potentiation by propofol and etomidate was 
unaltered [4]. The γ2S280I mutation, which reports 
on the involvement of the γ+/β- interface, altered the 
potentiation of both anesthetics [4], thus indicating that 
these anesthetics are acting at this interface. Photoaffinity 
labeling propofol analogs has also identified residues in 
the γ+/β- interface [3, 5], but the importance for function 
was not clear.
Introduction of the β2N265I reporter mutation 
located at both β+/α- interfaces, eliminated potentiation 
by etomidate and propofol [4]. Several point mutations 
of β2N265 have shown its importance of this residue 
for modulation by etomidate and propofol [see 3, 4 and 
references therein], though no photoaffinity labeling has 
ever been observed. Labeling of other residues at the 
β+/α- interface(s) has indicated presence of binding sites 
for etomidate and propofol [3, 5], while the contribution 
of individual sites could not be differentiated. By using 
receptor concatenation and the β2N265I mutation, we 
individually altered one of the two sites, and were able 
to dissect the functional contribution of the two β+/α- 
interfaces. Etomidate acted almost exclusively at the 
β+/α- interface flanked by γ and β subunits with a minor 
contribution of the β+/α- interface flanked by α and γ 
subunits [4]. In contrast to etomidate, both interfaces were 
similarly important for modulation by propofol. 
Figure 1: Schematic representation of α1β2γ2 GABAA 
receptors: Cross section of the receptor with the 
extracellular domain removed. Shown in blue are residues 
mutated in each subunit. Arrows indicate the subunit interfaces.
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The importance of the corresponding binding 
pockets for anesthetic action is underlined by the fact 
that recently two new allosteric modulators of GABAA 
receptors were identified that excert their action 
exclusively through the β+/α- interfaces. Similar to 
etomidate they predominantly act at the β+/α- interface 
flanked by γ and β subunits, but in contrast to etomidate 
they do not act at the γ+/β- subunit interface. Both 
substances induced loss of righting reflex in Xenopus 
laevis tadpoles with potencies similar to propofol [6] and 
represent leads for the development of novel anesthetics. 
In summary, we have demonstrated that etomidate 
exerts its function predominantly through the γβ+/α-β and 
γ+/β- subunit interfaces while propofol acts predominantly 
at the γβ+/α-β, αβ+/α-γ and γ+/β- subunit interfaces. 
GABAA receptors harbor modulatory sites for these 
anesthetics in three of the five-subunit interfaces. The 
anesthetics etomidate and propofol use a different sub-set 
each. Pentobarbital seems to use at least one additional 
interface [4]. Taken together, these data demonstrate the 
existence of an asymmetry in potentiation of the α1β2γ2 
GABAA receptor by these popular intravenous anesthetics.
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